CTOs on the Move

Visa Solutions Healthcare

www.visasolutionshealthcare.com

 
Visa Solutions Healthcare is a healthcare division that connects partners with highly qualified international registered nurses and allied clinicians. They offer a Care for your Dream program to help nurses work in the U.S. and provide diagnostics so...
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Right Trend

Right Trend is a Bellerose, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

American College of Gastroenterology

The American College of Gastroenterology is a professional organization with an international membership of over 17,000 individuals from 86 countries. The College provides its members with the most accurate and up to date scientific information on dige...

Envisia Therapeutics

Envisia Therapeutics, formed by Liquidia Technologies in 2013, is a privately held biotechnology company focused on the development of novel ocular therapies. Envisia is leveraging the unique and powerful properties of the PRINT® platform to develop therapies for a variety of ocular conditions, the most advanced of which is ENV515, for the treatment of glaucoma. ENV515 is a novel extended-release formulation of a prostaglandin analogue formulation. It has the potential to significantly limit disease progression and vision loss through improved product performance and patient compliance. Envisia is located in Research Triangle Park, North Carolina.

Baptist St. Anthony Health System

Baptist St. Anthony Health System is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Amarillo, TX. To find more information about Baptist St. Anthony Health System, please visit www.bsahs.org

Scynexis

SCYNEXIS, Inc. is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. Our scientists have extensive experience in the life sciences industry having, together and individually, been involved in the discovery and development of innovative medicines over a broad range of therapy areas. We are developing our lead product candidate, SCY-078, a novel antifungal in Phase 2, as a novel oral and intravenous drug for the treatment of serious and life-threatening invasive fungal infections in humans.